AVP and papilloma: One explanation for our relatively low upgrade rate could be, that we excluded papillary lesions or RS/CSL containing larger cellular atypia from the group “Papillomas/RS” and put them into the group with ADH, FEA, and LN1-2, since cellular atypia is the clinically dominant lesion.